Emyria’s Empax Centre Selected For Key MDMA Trial

Emyria Ltd (ASX:EMD) has revealed that its Empax Centre has been selected as a key site for an MDMA trial sponsored by New York-based Transcend Therapeutics.

With a state-of-the-art facility, the Empax Centre is dedicated to the evaluation of new treatments for mental health, providing critical infrastructure for clinical trials and real-world settings.

Notably, the trial will assess the safety and efficacy of methylone ( MDMA analogue), a novel neuroplastogen promoting nerve cell growth in areas affected by PTSD, depression, and anxiety.

Trial highlights

Methylone, identified as TSND-201 by Transcend Therapeutics, is an MDMA analogue showing promise in rapidly activating neuroplasticity gene expression crucial for recovery in neuropsychiatric disorders.

The Phase 2 trial, titled “IMPACT-2” (Investigation of Methylone for PTSD), plans to enroll up to 79 participants across multiple sites in Australia and the United States.

Dr. Michael Winlo, CEO of Emyria, stated, “We are delighted to work with Transcend Therapeutics on this exciting trial that highlights our dedication to bringing new treatments to our patients while utilising the full capabilities of our Empax Centre.

“Site selection is international recognition of our team’s unique capabilities and we look
forward to working with Transcend Therapeutics and our network of specialists to advance
this trial and improve mental health outcomes for patients with severe PTSD.”

Trial details

About Transcend Therapeutics

Transcend Therapeutics is a clinical-stage, neuroscience-focused company focused on developing rapid-acting treatments for neuropsychiatric diseases.

The company is advancing TSND-201 (methylone) as a robust solution for PTSD, Major Depressive Disorder (MDD), and other central nervous system conditions.

As a Public Benefit Corporation, Transcend allocates 10% of its founding shares to nonprofits supporting scientific research and increasing access to mental health solutions.



JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.